Roche Sets Sights on Obesity Markets

In a Phase Ib study, Roche’s treatment acquired during the Carmot acquisition—exhibited an 18.8% reduction in body fat.

As it publishes promising findings from the Phase Ib study of its experimental overweight and type 2 diabetes medication, Roche is hoping to partake in the lucrative revenue gained from obesity medicines.

The treatment works comparatively to Eli Lilly’s Mounjaro, that based on Lilly’s financials brought in $1.81 billion in revenue in the first quarter of 2024.

About 96 overweight or obese people that both and don’t have Type 2 diabetes were included in the placebo phase study. After 24 weeks, the average placebo adjusted decrease in weight was 18.8%.

In the therapy group, every individual had a body mass reduction in excess of 5%, and 45% of individuals lost over 20% of their initial weight. After 24 weeks, the therapy group members who had pre-diabetic classification became normoglycemic.